NY-MOTIVE-PARTNERS
12.7.2022 09:02:10 CEST | Business Wire | Press release
Motive Partners ("Motive"), a leading specialized private equity firm focused on financial technology, today announced the successful final close of its second flagship fund, Motive Capital Fund 2 (the "Fund"), with total capital commitments of $2.54 billion for the Fund and its affiliated co-investment vehicles.
The Fund employs the same investment strategy executed in Motive Partners' inaugural flagship fund. The Fund focuses on growth and buyout investments in software, investment and information services businesses located in North America and Europe. The Fund has already partnered with ten companies - InvestCloud, Insurify, Wilshire, Trumid, Motive Capital Corp II, CAIS, FNZ, Forge Global, BetaNXT and Backbase.
Commitments to the Fund were secured from a geographically diverse group of investors, including public and private pensions, sovereign wealth funds, foundations, financial institutions, institutional fund managers, family offices and high net worth individuals. Existing investors from the inaugural fund were joined by a significant group of new investors.
Rob Heyvaert, Founder & Managing Partner at Motive Partners , commented: "We are deeply grateful for the support from our existing investors and are delighted to welcome a roster of new partners to the Motive family - thank you for your trust. We will continue to be laser-focused on partnering transformational capital with world-class management teams."
During the fundraising period, Motive continued to invest behind its integrated approach, building out the Motive team to include over 180 Investors, Operators and Innovators.
Bob Brown, Founding Partner & Head of Investor Relations , commented: "We greatly appreciate the support of such an esteemed and diverse group of investors, and we take seriously the responsibility that our investors have bestowed upon us. We continue to invest into our distinct operating capabilities, allowing us to identify attractive investment opportunities and support our portfolio companies in the next stage of their growth."
About Motive Partners
Founded in 2016, Motive Partners is a specialist private equity firm with offices in North America and Europe, focused on backing, building, and buying technology companies that enable the financial economy. At the time of the final closing of the Fund, Motive Partners has over $5.5 billion in regulatory assets under management and has established an integrated team of over 180 Investors, Operators and Innovators. The firm focuses on growth equity and buyout investments in software, investment and information services companies in North America and Europe, serving five primary subsectors: Banking & Payments, Capital Markets, Data & Analytics, Wealth & Investment Management, and Insurance. Motive Partners is a privately held firm majority-owned by its partners, and brings differentiated expertise, connectivity, and capabilities to create long-term value in financial technology companies.
More information on Motive Partners can be found at www.motivepartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005158/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom